BED has quickly become a drug market ripe with opportunity due to a growing diagnosed patient population - a trend that should be encouragement enough for pharmaceutical companies to begin investing heavily in BED drug development.
James Mather, Pharma Analyst at Publisher, comments:
"Over the next decade, we expect the increasing awareness of BED among both physicians and the general public to drive an increase in the diagnosis rate. The growing diagnosed population, coupled with clinicians steadily becoming more comfortable with pharmacotherapy for BED, will result in substantial growth in the market. GlobalData forecasts that the number of BED patients receiving drug therapy will more than triple over the next decade."
In 2017, the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) had 197,076 diagnosed prevalent cases of BED. GlobalData epidemiologists expect the diagnosed prevalent cases of BED in the 7MM to increase to 204,424 cases by 2027, at an AGR of 0.37%. The US will have the highest growth in the diagnosed prevalent cases of BED in the 7MM from 2017–2027, while France will have the lowest growth in the diagnosed prevalent cases of BED from 2017–2027. Germany, Italy, and Japan will see a decline in the number of diagnosed prevalent cases of BED during the forecast period at negative AGRs of 0.54%, 0.05%, and 0.43%, respectively.